David Reese, Amgen
Amgen's promising gastric cancer drug makes good on Five Prime potential with FDA's breakthrough nod
When Five Prime — now part of Amgen — rolled out mid-stage data for gastric cancer candidate bemarituzumab late last year, it looked like a big win …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
